64356-03-2

Basic information

• Product Name: 2-bromo-4-n-butylacetophenone
• Synonyms: 2-bromo-4-n-butylacetophenone;2-bromo-1-(4-butylphenyl)ethanone
• CAS NO: 64356-03-2
• Molecular Formula: C₁₂H₁₅BrO
• Molecular Weight: 255.15
• Mol File: 64356-03-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 320.5°C at 760 mmHg
• Flash Point: 47.1°C
• Appearance: /
• Density: 1.275g/cm³
• Vapor Pressure: 0.000316mmHg at 25°C
• Refractive Index: 1.54
• CAS DataBase Reference: 2-bromo-4-n-butylacetophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-4-n-butylacetophenone(64356-03-2)
• EPA Substance Registry System: 2-bromo-4-n-butylacetophenone(64356-03-2)

Safety Data

• Hazardous Substances Data: 64356-03-2(Hazardous Substances Data)

Usage

General Description

2-bromo-4-n-butylacetophenone, also known as bromofenac, is a chemical compound with the molecular formula C12H15BrO. It is a white to off-white crystalline solid that is commonly used as a pharmaceutical intermediate in the synthesis of various medications. 2-bromo-4-n-butylacetophenone is a ketone derivative and is often used as a building block in the manufacture of non-steroidal anti-inflammatory drugs (NSAIDs). It is also used in the production of other organic compounds and is known for its mild analgesic and anti-inflammatory properties. 2-bromo-4-n-butylacetophenone is a versatile chemical that is widely employed in the pharmaceutical industry for its role as a key intermediate in the synthesis of various therapeutic agents.

InChI:InChI=1/C12H15BrO/c1-2-3-4-10-5-7-11(8-6-10)12(14)9-13/h5-8H,2-4,9H2,1H3

Upstream product

• 186581-53-3 diazomethane 
• 28788-62-7 4-butylbenzoyl chloride 
• 147795-77-5 4-n-Butylphenyl-1-bromoacetylene 
• 104-51-8 1-butylbenzene 
• 37920-25-5 1-(4-butylphenyl)ethanone 

Downstream Products

• 96498-43-0 Piperidine-1-carbodithioic acid 2-(4-butyl-phenyl)-2-oxo-ethyl ester 
• 1359983-61-1 4-(4-butylphenyl)-1H-imidazol-2-amine hydrochloride 
• 29307-88-8 Essigsaeure-p-n-butylbenzoylmethyl-ester 
• 313957-02-7 2-[4-(4-butylphenyl)thiazol-2-yl]-3-(4-hydroxy-3-ethoxyphenyl)acrylonitrile 
• 1430109-89-9 (E)-1-(4-butylphenyl)-4-(4-methoxyphenyl)but-2-ene-1,4-dione 
• 102158-72-5 (E)-1-(4-butylphenyl)-4-phenylbut-2-ene-1,4-dione 
• 905590-53-6 (2-amino-4-phenyl-1,3-thiazol-5-yl)(4-butylphenyl)methanone 
• 139870-17-0 (R)-4-[2-(4-Butyl-phenyl)-2-oxo-ethoxy]-5-((S)-1,2-dihydroxy-ethyl)-3-hydroxy-5H-furan-2-one 

Relevant articles and documents

Identification of Anti-Mycobacterial Biofilm Agents Based on the 2-Aminoimidazole Scaffold

Tuberculosis (TB) remains a significant global health problem for which new therapeutic options are sorely needed. The ability of the causative agent, Mycobacterium tuberculosis, to reside within host macrophages and form biofilm-like communities contributes to the persistent and drug-tolerant nature of the disease. Compounds that can prevent or reverse the biofilm-like phenotype have the potential to serve alongside TB antibiotics to overcome this tolerance, and decrease treatment duration. Using Mycobacterium smegmatis as a surrogate organism, we report the identification of two new 2-aminoimidazole compounds that inhibit and disperse mycobacterial biofilms, work synergistically with isoniazid and rifampicin to eradicate preformed M. smegmatis biofilms in vitro, are nontoxic toward Galleria mellonella, and exhibit stability in mouse plasma.

2-(4-ARYL-1H-IMIDAZOL-1-YL)ANILINE COMPOUNDS

The present invention provides compounds that are useful as vaccine adjuvants and/or antitumor agents and methods for producing and using the same. In one particular aspect of the invention, compounds of the invention are of the formula (I) where R1, R2, R3 and Ar1 are those defined herein.

2-Arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands

The invention concerns novel 2-arylimino-2,3-dihydrothiazole derivatives of general formula (I), their preparation methods and their use as medicines, in particular for treating pathological conditions or diseases wherein one (or several) somatostatin receptors is/are involved. Said pathological conditions include in particular acromegaly, pituitary adenoma or endocrine gastroenteropanceatic tumors including the carcinoid syndrome, and gastrointestinal bleeding. In general formula (I), R1 represents in particular an alkyl, aralkyl, cyclohexyl radical optionally substituted by an amino radical or R1 represents a —C(R11)(R12)—CO—R10 radical wherein R11 represents H, R12 represents in particular H, carbocyclic or heterocyclic alkyl, cycloalkyl or aralkyl and R10 represents in particular an aminoalkylamino radical; R2 represents a carcyclic or heterocyclic aryl radical optionally substituted; R3 represents in particular COR5 or a carbocyclic or heterocyclic alkyl, adamantyl, aryl radical optionally substituted, carbocyclic or heterocyclic aralkyl optionally substituted on the aryl group; and R5 represents a radical fixed by a nitrogen atom to the group CO.